BR112021008200A2 - Composições e métodos para distúrbios de alfa-1-antitripsina - Google Patents

Composições e métodos para distúrbios de alfa-1-antitripsina

Info

Publication number
BR112021008200A2
BR112021008200A2 BR112021008200A BR112021008200A BR112021008200A2 BR 112021008200 A2 BR112021008200 A2 BR 112021008200A2 BR 112021008200 A BR112021008200 A BR 112021008200A BR 112021008200 A BR112021008200 A BR 112021008200A BR 112021008200 A2 BR112021008200 A2 BR 112021008200A2
Authority
BR
Brazil
Prior art keywords
alpha
compositions
antitrypsin
methods
disorders
Prior art date
Application number
BR112021008200A
Other languages
English (en)
Inventor
Aaron Sato
Mark Desouza
Original Assignee
Spin Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spin Therapeutics Llc filed Critical Spin Therapeutics Llc
Publication of BR112021008200A2 publication Critical patent/BR112021008200A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições e métodos para distúrbios de alfa-1-antitripsina. são divulgados aqui composições e métodos úteis para tratar uma deficiência de alfa-1-antitripsina.
BR112021008200A 2018-10-29 2019-10-29 Composições e métodos para distúrbios de alfa-1-antitripsina BR112021008200A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752182P 2018-10-29 2018-10-29
PCT/US2019/058673 WO2020092448A1 (en) 2018-10-29 2019-10-29 Compositions and methods for alpha-1-antitrypsin disorders

Publications (1)

Publication Number Publication Date
BR112021008200A2 true BR112021008200A2 (pt) 2021-12-14

Family

ID=68771752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021008200A BR112021008200A2 (pt) 2018-10-29 2019-10-29 Composições e métodos para distúrbios de alfa-1-antitripsina

Country Status (9)

Country Link
US (1) US20210388059A1 (pt)
EP (1) EP3873926A1 (pt)
JP (1) JP2022509517A (pt)
KR (1) KR20210111245A (pt)
CN (1) CN113286816A (pt)
AU (1) AU2019369403A1 (pt)
BR (1) BR112021008200A2 (pt)
CA (1) CA3117961A1 (pt)
WO (1) WO2020092448A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157359A1 (en) * 2020-05-28 2023-04-05 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of serpina1
CN117942275A (zh) * 2022-10-31 2024-04-30 康码（上海）生物科技有限公司 一种基于病毒阻断剂的洗手液及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
ES2252070T3 (es) 1999-10-13 2006-05-16 Immunex Corporation Vectores y procedimientos para la expresion de proteinas recombinantes.
JP2003531590A (ja) * 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
KR20040089608A (ko) 2002-02-07 2004-10-21 델타 바이오테크놀로지 리미티드 Ｈｉｖ 억제 단백질
US8341615B2 (en) 2008-07-11 2012-12-25 International Business Machines Corporation Single instruction multiple data (SIMD) code generation for parallel loops using versioning and scheduling
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR20210032558A (ko) * 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
EP2802653A4 (en) * 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
CN107206257A (zh) * 2014-10-27 2017-09-26 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制剂融合多肽和其使用方法
US20200102575A1 (en) * 2017-03-29 2020-04-02 Cornel! University Oxidation-resistant aat gene therapy

Also Published As

Publication number Publication date
JP2022509517A (ja) 2022-01-20
CN113286816A (zh) 2021-08-20
EP3873926A1 (en) 2021-09-08
KR20210111245A (ko) 2021-09-10
AU2019369403A1 (en) 2021-05-20
WO2020092448A1 (en) 2020-05-07
US20210388059A1 (en) 2021-12-16
CA3117961A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
BR112018075833A2 (pt) composições compreendendo cepas bacterianas
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MD3804737T2 (ro) Compoziții care conțin tulpini bacteriene
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112016008541A2 (pt) composições úteis para tratar distúrbios relacionados a kit
BR112016000654A2 (pt) composições para a modulação de expressão de tau
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
BR112021008200A2 (pt) Composições e métodos para distúrbios de alfa-1-antitripsina
EA202191471A1 (ru) Противовоспалительные полипептиды
BR112018072664A2 (pt) composições e métodos para tratamento de inflamação e infecção do olho
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
BR112018076287A2 (pt) métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.